Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors

Next Previous
Search
Trial Profile

A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bintrafusp alfa (Primary) ; Cobolimab (Primary) ; Dostarlimab (Primary) ; Feladilimab (Primary) ; GSK 3174998 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Fluorouracil; Gemcitabine; Paclitaxel; Pemetrexed
  • Indications Bladder cancer; Carcinoma; Cervical cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Malignant-mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Acronyms INDUCE-1
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 31 Jul 2023 Status changed from active, no longer recruiting to completed.
    • 22 Nov 2022 According to Japic record, this trial has been discontinued for countries/regions: Japan / JapanNorth, America / North AmericaEurope, EuropeOceania / Oceania.
    • 25 Aug 2021 Planned End Date changed from 31 Dec 2024 to 20 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top